trending Market Intelligence /marketintelligence/en/news-insights/trending/DNpRd3TIzx39SulFNcdUGg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Zynerba Pharmaceuticals stock plummets as epilepsy drug fails phase 2 trial

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Zynerba Pharmaceuticals stock plummets as epilepsy drug fails phase 2 trial

Zynerba Pharmaceuticals Inc. said its epilepsy drug ZYN002 failed to meet its endpoints in a phase 2 trial.

The company was determining whether the cannabidiol gel could reduce the frequency of seizures in adult patients who were enrolled in the trial when compared to placebo.

Zynerba Pharmaceuticals shares were down nearly 59% to $6.19 as of 11:12 a.m. ET on Aug. 7.

The setback is not the end of the therapy though. The gel is also being investigated in patients with osteoarthritis and children with the Fragile X syndrome, with phase 2 clinical trial results expected in August and September, respectively.